➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Baxter
Moodys
Boehringer Ingelheim
AstraZeneca

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 10,507,244

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,507,244
Title:Anti-TIGIT antigen-binding proteins and methods of use thereof
Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to TIGIT and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.
Inventor(s): Hicklin; Daniel (Montclair, NJ), Winston; William (Marlborough, MA), Seidel-Dugan; Cynthia (Belmont, MA), Nielson; Nels P. (Lebanon, NH)
Assignee: Potenza Therapeutics, Inc. (Cambridge, MA)
Application Number:15/627,161
Patent Claims:see list of patent claims

Details for Patent 10,507,244

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck Sharp Dohme KEYTRUDA pembrolizumab POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER 125514 001 2014-09-04   Start Trial Potenza Therapeutics, Inc. (Cambridge, MA) 2035-10-01 RX Orphan search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125527 001 2015-03-04   Start Trial Potenza Therapeutics, Inc. (Cambridge, MA) 2035-10-01 RX search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125527 002 2015-03-04   Start Trial Potenza Therapeutics, Inc. (Cambridge, MA) 2035-10-01 RX search
Bristol Myers Squibb OPDIVO nivolumab INJECTABLE;INJECTION 125554 001 2015-11-23   Start Trial Potenza Therapeutics, Inc. (Cambridge, MA) 2035-10-01 RX Orphan search
Genentech Inc TECENTRIQ atezolizumab INJECTABLE;INJECTION 761034 001 2017-04-17   Start Trial Potenza Therapeutics, Inc. (Cambridge, MA) 2035-10-01 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Moodys
Merck
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.